相关实验视频

Updated: Sep 19, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

阻断Tim-3增强CD8+T细胞活性,以抑制肝细胞癌在射频除后的复发

Na Wu¹, Xinru Pei¹, Weiguo Cai¹

¹Interventional Diagnostic and Therapeutic Center, Zhongnan Hospital of Wuhan University, Wuhan, China.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

|June 16, 2025

概括

肝细胞癌的不完整的射频除可以导致瘤的进展. 用抗Tim-3疗法准T细胞免疫球蛋白和粘素域3 (Tim-3) 有效地治疗残留瘤并提高抗PD-1治疗效率.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
癌症研究癌症研究

背景情况:

肝细胞癌 (HCC) 的不完全射频切除 (iRFA) 可能导致残留瘤进展和抗PD-1 治疗的耐药性.
在RFA后CD8+T细胞中T细胞免疫球蛋白和粘素域3 (Tim-3) 表达率升高,降低了HCC患者的抗瘤免疫反应.

研究的目的:

为了研究抗Tim-3疗法在治疗iRFA后残留的HCC瘤的有效性.
探索HCC残留瘤中抗Tim-3治疗的潜在机制.
为了评估对HCC残留瘤的anti-Tim-3和anti-PD-1的联合治疗.

主要方法:

在iRFA后的小鼠模型中检查了残留HCC瘤中的Tim-3表达.
用抗αTim-3治疗残留瘤并评估有效性.
利用转录组测序来阐明机制.
对抗αTim-3和抗αPD-1的评估组合疗法.

主要成果:

在iRFA后残留瘤中的CD8+T细胞中观察到提升的Tim-3表达,与加速瘤进展相关.
抗αTim-3治疗通过增加CD8+T细胞透和抗瘤活性来抑制残留瘤生长.
抗αTim-3疗法上调了PD-1表达,与抗αPD-1的联合疗法诱导了强大的抗瘤免疫反应.

结论:

在iRFA后CD8+T细胞中提升的Tim-3表达有助于HCC残留瘤的进展.
抗αTim-3疗法在减缓瘤进展和增强抗PD-1治疗反应方面表现有前途.

关键词:

不完全的无线电频率剥离.在PD-1中使用PD-1.蒂姆-3的时间.肝细胞癌是肝细胞癌.免疫疗法免疫疗法

更多相关视频

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...